Addison's Disease — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Primary adrenal insufficiency in patients with bilateral adrenal metastases treated with curative ablative radiation therapy: A comprehensive review of literature and expert agreements for radiation practice.
Bennassi Alexander et al. — Clinical and translational radiation oncology (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42255979/
- 2.
Organoid-like Functional Adrenal Gland Cortex Derived From Human Pluripotent Stem Cells
McAlpine J et al. (1 July 2026)
https://doi.org/10.64898/2026.06.30.735632
- 3.
Group education improves self-management of adrenal insufficiency in patients and their relative.
Åkerman AK et al. (29 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42370942/
- 4.
Secondary Adrenal Insufficiency Exacerbated by Switching Inhaled Corticosteroids: A Case of Steroid Withdrawal Syndrome.
Shirai R et al. (27 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42366037/
- 5.
Approach to thyroid disorders associated with immune checkpoint inhibitors and tyrosine kinase inhibitors.
Padhye V et al. (26 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42361349/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Addison's Disease
Addison's Disease is a rare disorder in which the adrenal glands do not produce sufficient steroid hormones, particularly cortisol and aldosterone. Affecting roughly 1 in 10,000 Australians, it requires lifelong hormone replacement therapy. Adrenal crises triggered by illness or injury can be life-threatening if not treated promptly.
Most Recent Research
BACKGROUND: Bilateral adrenal metastases are rare but clinically significant. While stereotactic body radiotherapy (SBRT) provides excellent local control, the risk of post-treatment primary adrenal insufficiency (PAI) after bilateral irradiation remains poorly defined and lacks standardized management guidelines. METHODS: We performed a comprehensive literature review following PRISMA principles, using PubMed and Embase databases (January 1956 to June 2025). Studies including patients with bilateral adrenal metastases treated with radiotherapy, or unilateral irradiation in the setting of a solitary adrenal gland, were eligible. Data on treatment characteristics, incidence of PAI, diagnostic approaches, and management were extracted. In parallel, a multidisciplinary expert panel developed expert opinion-based practical recommendations for the screening, treatment, and follow-up of PAI. RESULTS: Thirty studies comprising 156 patients treated with bilateral adrenal irradiation (or irradiation of a solitary adrenal gland) were included. PAI was reported in 47 patients (30%), although systematic endocrine evaluation was performed in only a minority of studies, suggesting potential underestimation. Time to onset ranged from 3 to 30 months. Reporting of diagnostic work-up, management, and follow-up was highly heterogeneous, and treatment details were frequently lacking. No study identified reliable dosimetric predictors of PAI, and no association between radiation dose parameters and adrenal insufficiency was demonstrated. CONCLUSIONS: PAI following bilateral adrenal radiotherapy is likely under-recognized and under-reported, with clinically meaningful incidence and potential life-threatening consequences. In the absence of robust data, systematic hormonal assessment, careful treatment planning, and structured long-term follow-up are essential. We propose practical, expert-based recommendations to guide clinical management, while emphasizing the need for prospective studies to better define incidence, risk factors, and optimal prevention strategies.
Common Questions
What is Addison's Disease?
Addison's Disease is a rare disorder in which the adrenal glands do not produce sufficient steroid hormones, particularly cortisol and aldosterone. Affecting roughly 1 in 10,000 Australians, it requires lifelong hormone replacement therapy. Adrenal crises triggered by illness or injury can be life-threatening if not treated promptly.
How many clinical trials are available for Addison's Disease?
RareWays currently indexes 107 clinical trials for Addison's Disease, of which 10 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Addison's Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Addison's Disease.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.